Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Beijing InnoCare Pharma Tech Co., Ltd.)"
Count: 40
Selected: 0
| NCT ID | Title |
|---|
| NCT06004856 | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia | ||
| NCT05745623 | A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors | ||
| NCT05728658 | The Study of ICP-248 in Patients With Mature B-cell Malignancies | ||
| NCT05719701 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma | ||
| NCT05702268 | Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis | ||
| NCT05690581 | Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects With Advanced Solid Tumors | ||
| NCT05688696 | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus | ||
| NCT05684653 | Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject | ||
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | ||
| NCT05660720 | Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects | ||
| NCT05552937 | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | ||
| NCT05451199 | A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis | ||
| NCT05399030 | A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects | ||
| NCT05372120 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | ||
| NCT05370755 | A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | ||
| NCT05367232 | A Study of ICP-033 in Patients With Advanced Solid Tumors | ||
| NCT05316857 | DDI Study of Orelabrutinib | ||
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | ||
| NCT05232149 | A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia | ||
| NCT05210868 | A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | ||
| NCT05051891 | A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma | ||
| NCT04711148 | A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis | ||
| NCT04685226 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | ||
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | ||
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | ||
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | ||
| NCT04441450 | ADME Study of [14C]ICP-022 in Healthy Males | ||
| NCT04440059 | A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia | ||
| NCT04438044 | A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | ||
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL | ||
| NCT04305197 | A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) | ||
| NCT04304040 | A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma | ||
| NCT04014205 | A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies | ||
| NCT03797456 | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | ||
| NCT03758664 | Clinical Study of ICP-192 in Solid Tumors Patients | ||
| NCT03642834 | Study of ICP-105 in Solid Tumors Patients | ||
| NCT03494179 | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | ||
| NCT03493217 | A Study to Evaluate ICP-022 in Patients With CLL/ SLL | ||
| NCT05978739 | Evaluating Different Doses of Orelabrutinib in MCL | ||
| NCT05284175 | A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder |
